About
Vifor Pharma AG, a pharmaceutical company, focuses on the development, manufacture, and commercialization of pharmaceutical products in Switzerland, rest of Europe, the United States, and internationally. The company offers Ferinject/Injectafer, a solution of ferric carboxymaltose used for the treatment of iron deficiency and iron deficiency anemia; Maltofer, an oral iron polymaltose complex for infants, children, adolescents, and pregnant woman with iron deficiency; and Mircera, a long-acting erythropoiesis-stimulating agent (ESA) to treat symptomatic anemia associated with the chronic kidney disease (CKD). It also provides Retacrit, a short-acting ESA; Venofer, an intravenous iron sucrose used in the intravenous treatment of iron deficiency; and Velphoro, a non-calcium, iron-based chewable phosphate binder for the treatment of hyperphosphatemia in adults with CKD undergoing dialysis.
Similar securities
Based on sector and market capitalization